AmritaGen’s Cap-Exosomes Mediated Drug Delivery to the brain.
Systemic delivery of Cap-exosomes loaded with specific genes and/or FDA-approved drug molecules will have the potential, unlike other sAD therapies currently under developments to rebuild brain circuits and stimulate neuro-glia-vascular synchronized activity that is impaired in patients with mild cognitive impairments (MCI) and sAD patients.
“AmritaGen Inc.: Bringing Proprietary Targeted Exosomes Production Technology to the World of Medicine.”
Interested in Collaborating or partnering with us please contact us.
AmritaGen, Inc
About Us
AmritaGen is pioneering the discovery and development of a new gene therapy method for delivering combination of drugs for the treatment of neurodegenerative diseases such as Alzheimer’s disease (AD), sporadic AD (sAD)), Parkinson disease, stroke, and Traumatic Brain Injury.
About Us
MISSION
Delivery of drugs to the brain for the treatment of neurodegenerative diseases.
About Us
VISION
A world with effective therapy for the treatment of neurodegenerative diseases.
Our Team
James W. Simpkins, PhD., Chairman & Founder
Saumyendra N Sarkar, Ph.D Founder, President, and Chief Scientific Officer
Kissaou Tchedre, PhD., MBA, Co-founder and Chief Executive Officer
Dr. Elizabeth (Liz) Engler-Chiurazzi is an Assistant Professor, Advisory Board
Candice M. Brown, PhD is an Assistant Professor, Advisory Board
Deborah Corbin, Advisory Board
